Nordic Pharma's Lacrimal Gel Presentation at SECO 2025
Nordic Pharma, a subsidiary of Nordic Group B.V., has recently announced an exciting poster presentation at an important optometric conference. This presentation will feature the innovative Lacrimal Gel, LACRIFILL, designed for treating various cases of dry eye disease. The event, known for its educational significance in the field of optometry, promises to highlight cutting-edge developments and treatments.
Details of the Poster Presentation
The SECO 2025 conference, which will take place in Atlanta, offers an incredible platform for the presentation of new research and treatment methods in ocular care. A significant focus of this year's event will be a case series presented by Dr. Mile Brujic from Premier Vision Group. The case series will cover the effective use of LACRIFILL Canalicular Gel in patients suffering from refractory dry eye disease, showcasing its potential in improving patient outcomes.
What is LACRIFILL Canalicular Gel?
LACRIFILL is a revolutionary hyaluronic acid (HA) gel that is conveniently contained in a pre-loaded, single-use syringe. This product enables healthcare professionals to effectively deliver the gel into the canaliculus through the punctum, significantly enhancing the experience for both practitioners and patients. The gel has shown remarkable results in alleviating symptoms associated with severe dry eye conditions.
Positive Results from Case Series
Dr. Brujic has expressed enthusiasm about the findings from his patient case series. According to him, LACRIFILL Canalicular Gel has demonstrated significant improvements in corneal health and comfort. Specifically, patients who previously used dissolvable plugs for ocular occlusion exhibited enhanced results when treated with this new gel. Such findings highlight its potential role in advancing dry eye management strategies.
Overview of SECO International Conference
The SECO International conference draws attention worldwide as one of the largest optometric gatherings every year. This premier event provides attendees with diverse learning opportunities, insights into new research, and networking with other healthcare professionals. The poster presentation from Nordic Pharma will contribute valuable knowledge to the existing discourse on ocular therapies.
Statements from Nordic Pharma Leadership
Commenting on the important role of LACRIFILL in dry eye treatments, Phil Gioia, President of Nordic Pharma's U.S. team, underscored the exciting outcomes observed in practice. The collaboration with Optometrists continues to expand as Nordic Pharma seeks to empower eye care professionals with effective tools for managing dry eye conditions.
Conference Presentation Details
For those attending SECO 2025, here are key details regarding the presentation on LACRIFILL:
- Title: Novel Canalicular Gel for Lacrimal Occlusion: Case Series
- Presenting Author: Dr. Mile Brujic, OD, FAAO
- Date and Time: February 28, 2025, from 9:45 AM to 11:45 AM
- Location: Georgia World Congress Center, Hall A-1 and A-2, Bldg A-Level 1, Optometry's Marketplace™
Following the conference, attendees can access additional resources and information on online platforms that host these informative presentations.
About Nordic Group B.V.
Nordic Group B.V. is a dynamic international pharmaceutical company that focuses on developing and commercializing specialty products across various therapeutic areas, including Eye Care, Rheumatology, and Women's Health. The company has built a robust portfolio, mainly through strategic acquisitions and enhancements, and has established a strong presence in multiple markets.
Nordic Pharma's Expertise
Nordic Pharma, Inc. acts as a valuable partner to well-recognized global biopharmaceutical companies. Their expertise in biotechnology-derived medicines, state-of-the-art manufacturing technologies, and rigorous quality standards positions them uniquely in the industry.
Frequently Asked Questions
1. What is LACRIFILL Canalicular Gel?
LACRIFILL Canalicular Gel is a novel hyaluronic acid gel designed for managing refractory dry eye disease by occlusion in the canaliculus.
2. Who presented the case series at SECO 2025?
The case series was presented by Dr. Mile Brujic, OD, FAAO, during the conference.
3. When is the SECO 2025 conference taking place?
The conference occurs from February 26 to March 2, 2025, in Atlanta.
4. What are the benefits of using LACRIFILL?
Patients have reported significant improvements in comfort and corneal health after using LACRIFILL for dry eye management.
5. What areas does Nordic Group B.V. focus on?
Nordic Group B.V. specializes in products for Eye Care, Rheumatology, and Women's Health, expanding its portfolio through targeted developments.
